OBJECTIVE: Estimates for the contribution of transmission arising from acute HIV infections (AHIs) to overall HIV incidence vary significantly. Furthermore, little is known about AHI-attributable transmission among people who inject drugs (PWID), including the extent to which interventions targeting chronic infections (e.g. HAART as prevention) are limited by AHI transmission. Thus, we estimated the proportion of transmission events attributable to AHI within the mature HIV epidemic among PWID in New York City (NYC). DESIGN: Modeling study. METHODS: We constructed an interactive sexual and injecting transmission network using an agent-based model simulating the HIV epidemic in NYC between 1996 and 2012. Using stochastic microsimulations, we cataloged transmission from PWID based on the disease stage of index agents to determine the proportion of infections transmitted during AHI (in primary analyses, assumed to last 3 months). RESULTS: Our calibrated model approximated the epidemiological features of the mature HIV epidemic in NYC between 1996 and 2012. Annual HIV incidence among PWID dropped from approximately 1.8% in 1996 to 0.7% in 2012. Over the 16-year period, AHI accounted for 4.9% (10th/90th percentile: 0.1-12.3%) of incident HIV cases among PWID. The annualized contribution of AHI increased over this period from 3.6% in 1996 to 5.9% in 2012. CONCLUSION: Our results suggest that, in mature epidemics such as NYC, between 3% and 6% of transmission events are attributable to AHI among PWID. Current HIV treatment as prevention strategies are unlikely to be substantially affected by AHI-attributable transmission among PWID populations in mature epidemic settings.
OBJECTIVE: Estimates for the contribution of transmission arising from acute HIV infections (AHIs) to overall HIV incidence vary significantly. Furthermore, little is known about AHI-attributable transmission among people who inject drugs (PWID), including the extent to which interventions targeting chronic infections (e.g. HAART as prevention) are limited by AHI transmission. Thus, we estimated the proportion of transmission events attributable to AHI within the mature HIV epidemic among PWID in New York City (NYC). DESIGN: Modeling study. METHODS: We constructed an interactive sexual and injecting transmission network using an agent-based model simulating the HIV epidemic in NYC between 1996 and 2012. Using stochastic microsimulations, we cataloged transmission from PWID based on the disease stage of index agents to determine the proportion of infections transmitted during AHI (in primary analyses, assumed to last 3 months). RESULTS: Our calibrated model approximated the epidemiological features of the mature HIV epidemic in NYC between 1996 and 2012. Annual HIV incidence among PWID dropped from approximately 1.8% in 1996 to 0.7% in 2012. Over the 16-year period, AHI accounted for 4.9% (10th/90th percentile: 0.1-12.3%) of incident HIV cases among PWID. The annualized contribution of AHI increased over this period from 3.6% in 1996 to 5.9% in 2012. CONCLUSION: Our results suggest that, in mature epidemics such as NYC, between 3% and 6% of transmission events are attributable to AHI among PWID. Current HIV treatment as prevention strategies are unlikely to be substantially affected by AHI-attributable transmission among PWID populations in mature epidemic settings.
Authors: S R Friedman; A Neaigus; B Jose; R Curtis; M Goldstein; G Ildefonso; R B Rothenberg; D C Des Jarlais Journal: Am J Public Health Date: 1997-08 Impact factor: 9.308
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: Myron S Cohen; Christopher Dye; Christophe Fraser; William C Miller; Kimberly A Powers; Brian G Williams Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Lauren E Cipriano; Gregory S Zaric; Mark Holodniy; Eran Bendavid; Douglas K Owens; Margaret L Brandeau Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Meghan Bellerose; Lin Zhu; Liesl M Hagan; William W Thompson; Liisa M Randall; Yelena Malyuta; Joshua A Salomon; Benjamin P Linas Journal: Int J Drug Policy Date: 2019-11-15
Authors: Sara N Levintow; Brian W Pence; Teerada Sripaipan; Tran Viet Ha; Viet Anh Chu; Vu Minh Quan; Carl A Latkin; Vivian F Go; Kimberly A Powers Journal: PLoS One Date: 2022-10-14 Impact factor: 3.752